Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials
08 janv. 2025 08h00 HE
|
Replimune Group Inc
WOBURN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
23 déc. 2024 08h00 HE
|
Replimune Group Inc
WOBURN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...
Replimune Announces Pricing of Upsized Public Offering
25 nov. 2024 23h55 HE
|
Replimune Group Inc
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced...
Replimune Announces Proposed Public Offering
25 nov. 2024 07h09 HE
|
Replimune Group Inc
WOBURN, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
21 nov. 2024 16h05 HE
|
Replimune Group Inc
WOBURN, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
12 nov. 2024 08h00 HE
|
Replimune Group Inc
Completed Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) and remain on track to submit a BLA for RP1 plus nivolumab in anti-PD1 failed melanoma via...
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
09 nov. 2024 13h00 HE
|
Replimune Group Inc
Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity across all subgroups with injected and non-injected lesions responding with similar frequency, depth, duration,...
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 nov. 2024 16h01 HE
|
Replimune Group Inc
WOBURN, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
30 oct. 2024 09h15 HE
|
Replimune Group Inc
Late-breaking abstract featuring IGNYTE clinical trial data, including subgroup and initial biomarker analyses, selected for oral presentation Data from ARTACUS clinical trial of RP1 monotherapy in...
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 oct. 2024 16h01 HE
|
Replimune Group Inc
WOBURN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...